These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3122254)

  • 1. Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.
    Levy AD; Ellison GD
    Psychopharmacology (Berl); 1987; 93(2):218-22. PubMed ID: 3122254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function.
    El Hage C; Bédard AM; Samaha AN
    Neuropharmacology; 2015 Dec; 99():715-25. PubMed ID: 25823912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic haloperidol effects on oral movements and radial-arm maze performance in rats.
    Levin ED; Galen DM; Ellison GD
    Pharmacol Biochem Behav; 1987 Jan; 26(1):1-6. PubMed ID: 3562481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study.
    Cancela LM; Basso AM; Martijena ID; Capriles NR; Molina VA
    Brain Res; 2001 Aug; 909(1-2):179-86. PubMed ID: 11478934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of amphetamine-induced stereotypy and locomotion requires ongoing dopamine receptor activation.
    Conti LH; Segal DS; Kuczenski R
    Psychopharmacology (Berl); 1997 Mar; 130(2):183-8. PubMed ID: 9106917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation.
    Grimm JW; Kruzich PJ; See RE
    Pharmacol Biochem Behav; 1998 May; 60(1):167-73. PubMed ID: 9610939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphetamine-haloperidol interactions on striatal and mesolimbic tyrosine hydroxylase activity and dopamine metabolism.
    Kuczenski R
    J Pharmacol Exp Ther; 1980 Oct; 215(1):135-42. PubMed ID: 6109012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of striatal extracellular dopamine and dopamine metabolites by microdialysis in haloperidol-treated rats exhibiting oral dyskinesia.
    See RE
    Neuropsychopharmacology; 1993 Sep; 9(2):101-9. PubMed ID: 8216693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
    Bédard AM; Maheux J; Lévesque D; Samaha AN
    Schizophr Bull; 2013 May; 39(3):692-702. PubMed ID: 22927669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic amphetamine: is dopamine a link in or a mediator of the development of tolerance and reverse tolerance?
    Kuczenski R; Leith NJ
    Pharmacol Biochem Behav; 1981 Sep; 15(3):405-13. PubMed ID: 7291244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats.
    Andreassen OA; Weber C; Jørgensen HA
    Pharmacol Biochem Behav; 1999 Nov; 64(3):637-42. PubMed ID: 10548281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tremorous mouth movements in rats administered chronic neuroleptics.
    Ellison G; See R; Levin E; Kinney J
    Psychopharmacology (Berl); 1987; 92(1):122-6. PubMed ID: 2885880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia.
    See RE; Ellison G
    Eur J Pharmacol; 1990 Jun; 181(3):175-86. PubMed ID: 2384130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic neuroleptic treatment in rats produces persisting changes in GABAA and dopamine D-2, but not dopamine D-1 receptors.
    See RE; Aravagiri M; Ellison GD
    Life Sci; 1989; 44(3):229-36. PubMed ID: 2536879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of haloperidol at clinically recommended doses elicits smaller parkinsonian effects but more tardive dyskinesia in rats.
    Shireen E; Naeem S; Inam QU; Haleem DJ
    Pak J Pharm Sci; 2013 Mar; 26(2):271-6. PubMed ID: 23455196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in brain volume in response to estradiol levels, amphetamine sensitization and haloperidol treatment in awake female rats.
    Madularu D; Kulkarni P; Ferris CF; Brake WG
    Brain Res; 2015 Aug; 1618():100-10. PubMed ID: 26032742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of para-chlorophenylalanine on amphetamine and haloperidol-induced changes in striatal dopamine turnover.
    Kuczenski R
    Brain Res; 1979 Mar; 164():217-25. PubMed ID: 154937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.